Hong, David S <br/><br/>
Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer.  [electronic resource] 

 -  Investigational new drugs  Jun 2015 
 - 621-31 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1573-0646 
<br/><br/><label>Standard No.: </label>10.1007/s10637-015-0226-6  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies--adverse effects<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Agents--adverse effects<br/>Body Weight--drug effects<br/>Carcinoma, Non-Small-Cell Lung--diagnostic imaging<br/>Disease-Free Survival<br/>Energy Metabolism--drug effects<br/>ErbB Receptors--antagonists & inhibitors<br/>Female<br/>Humans<br/>Inflammation Mediators<br/>Interleukin-1alpha--antagonists & inhibitors<br/>Kaplan-Meier Estimate<br/>Lung Neoplasms--diagnostic imaging<br/>Male<br/>Middle Aged<br/>Quality of Life<br/>Radionuclide Imaging<br/>Treatment Outcome